🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.23
-0.46 (-5.29%)
Nov 18, 2026, 4:00 PM EST - Market closed

Enanta Pharmaceuticals Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Operating Revenue
6365.3267.6479.286.16
6365.3267.6479.286.16
Revenue Growth
-3.56%-3.42%-14.61%-8.07%-11.24%
Gross Profit
6365.3267.6479.286.16
Selling, General & Admin
36.8443.9357.8552.8945.48
Research & Development
88.55106.74131.48163.52164.52
Operating Expenses
125.38150.67189.33216.41210
Operating Income
-62.38-85.35-121.69-137.21-123.84
Interest Expense
-14.07-7.68-10.94-5.15-
Interest & Investment Income
8.239.9513.638.52.74
Other Non Operating Income (Expenses)
0.020.040.07-0.08
EBT Excluding Unusual Items
-68.21-83.05-118.93-133.85-121.02
Gain (Loss) on Sale of Investments
--0.51.142.86-1.17
Pretax Income
-68.21-83.55-117.79-131-122.19
Income Tax Expense
0.04-1.66-1.742.82-0.43
Net Income
-68.25-81.89-116.05-133.82-121.76
Net Income to Common
-68.25-81.89-116.05-133.82-121.76
Net Income Growth
-----
Shares Outstanding (Basic)
2921212121
Shares Outstanding (Diluted)
2921212121
Shares Change
35.93%0.85%0.90%1.78%2.14%
EPS (Basic)
-2.35-3.84-5.48-6.38-5.91
EPS (Diluted)
-2.35-3.84-5.48-6.38-5.91
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Free Cash Flow
--32.17-96.71-112.21-86.91
Free Cash Flow Per Share
--1.51-4.57-5.35-4.22
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-99.01%-130.66%-179.92%-173.23%-143.74%
Profit Margin
-108.33%-125.36%-171.58%-168.95%-141.31%
Free Cash Flow Margin
--49.24%-142.99%-141.67%-100.87%
EBITDA
-57.55-80.76-119.36-134.84-120.87
EBITDA Margin
-91.34%-123.63%-176.47%-170.24%-140.29%
D&A For EBITDA
4.834.592.342.372.97
EBIT
-62.38-85.35-121.69-137.21-123.84
EBIT Margin
-99.01%-130.66%-179.92%-173.23%-143.74%
Revenue as Reported
-65.3267.6479.286.16
SEC Filings: 10-K · 10-Q